The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Nontuberculous Mycobacterial Infection Market Projected To Become By 2030 Based On Its 2026 Valuation?
The nontuberculous mycobacterial infection market has seen substantial growth recently. It is anticipated to expand from $14.96 billion in 2025 to $15.87 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.1%. Historically, this growth can be attributed to several factors including a high incidence of pulmonary infections, limited effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, and low awareness among clinicians.
The nontuberculous mycobacterial infection market size is set to witness robust expansion in the coming years, forecast to achieve $21.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period is primarily driven by factors such as the increasing uptake of macrolide and rifampin combination therapies, improved accessibility to aminoglycosides, the evolution of personalized treatment strategies, the enlargement of hospital and specialty pharmacy networks, and the advancement of AI-enabled monitoring and diagnostic instruments. Significant trends characterizing this period include the rising adoption of macrolide and rifampin therapies, a heightened use of aminoglycoside-based treatments, the growing implementation of combination drug regimens, broader deployment of sophisticated diagnostic tools, and the increasing integration of AI-powered treatment monitoring.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Nontuberculous Mycobacterial Infection Market?
The increasing incidence of chronic obstructive pulmonary disease (COPD) is anticipated to boost the expansion of the nontuberculous mycobacterial infection market in the coming years. COPD is a long-term respiratory ailment marked by ongoing and often worsening restrictions in lung airflow. For individuals with COPD, nontuberculous mycobacterial (NTM) infections are linked to a more substantial reduction in forced expiratory volume in one second (FEV1) and a higher rate of exacerbations. This is because COPD can compromise the immune system and harm lung tissue, thereby facilitating NTM bacterial infection in the lungs. Illustratively, in September 2024, data from Public Health Scotland, a government health agency located in Scotland, indicated that in Scotland during 2022/23, the occurrence of COPD, determined by hospital admissions and death records, stood at 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Consequently, the growing prevalence of chronic obstructive pulmonary disease (COPD) is a key factor driving the growth of the nontuberculous mycobacterial infection market.
What Segment Groups Are Identified Within The Nontuberculous Mycobacterial Infection Market?
The nontuberculous mycobacterial infection market covered in this report is segmented –
1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin
2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy
3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin
4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine
What Trends Are Advancing Progress In The Nontuberculous Mycobacterial Infection Market?
Leading companies active in the nontuberculous mycobacterial infection market are prioritizing the development of advanced solutions, such as boron-based antibiotics, to boost treatment efficacy, overcome drug resistance, and improve patient outcomes. Boron-based antibiotics are small-molecule therapies designed to inhibit bacterial protein synthesis, offering potent and safer options for persistent infections. For instance, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, started enrolment in the Phase 3 part of its pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease, after concluding Phase 2 enrolments. Epetraborole, designed for oral administration, demonstrated potential in preclinical studies to treat Mycobacterium abscessus infections, aiming to shorten treatment duration, enhance tolerability, and address unmet medical needs in rare and serious infectious lung diseases, thereby supporting improved patient outcomes and disease management.
Which Companies Hold Significant Positions In The Nontuberculous Mycobacterial Infection Market?
Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.
Read the full nontuberculous mycobacterial infection market report here:
Which Regions Are Projected To Dominate The Nontuberculous Mycobacterial Infection Market In The Coming Years?
North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Nontuberculous Mycobacterial Infection Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp
Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2026, By The Business Research Company
Waterless Cosmetics Global Market Report
https://www.thebusinessresearchcompany.com/report/waterless-cosmetics-global-market-report
Mineral Cosmetics Global Market Report
https://www.thebusinessresearchcompany.com/report/mineral-cosmetics-global-market-report
Vegan Cosmetics Global Market Report
https://www.thebusinessresearchcompany.com/report/vegan-cosmetics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model